The city of Orlando, Florida, currently has 5 active clinical trials seeking participants for Pulmonary Fibrosis research studies.
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Recruiting
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
01/14/2025
Locations: Central Florida Pulmonary Group, PA, Orlando, Florida
Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants with Progressive Pulmonary Fibrosis
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Central Florida Pulmonary Group, Orlando, Florida
Conditions: Progressive Pulmonary Fibrosis
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
ALL
Ages:
40 years and above
Trial Updated:
12/10/2024
Locations: Central Florida Pulmonary Group PA, Orlando, Florida
Conditions: Idiopathic Pulmonary Fibrosis
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
10/17/2024
Locations: Central Florida Pulmonary Group, PA, Orlando, Florida
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
Recruiting
The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/25/2024
Locations: Central Florida Pulmonary Group, P.A. (CFPG) - Downtown Orlando, Orlando, Florida
Conditions: Idiopathic Pulmonary Fibrosis (IPF)